YLYu-Qin Liu

Yu-Qin Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu-Qin Liu has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Jian-Song Ren

    Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    5 shared publications
  • Ju-Fang Shi

    Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    5 shared publications
  • Ling-Bin Du

    Zhejiang Office for Cancer Control and Research, Zhejiang Cancer Hospital, Hangzhou, 310022, China

    5 shared publications
  • Xian-Zhen Liao

    Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China

    5 shared publications
  • A-Yan Mao

    Public Health Information Research Office, Institute of Medical Information, Chinese Academy of Medical Sciences, Beijing, 100020, China

    4 shared publications
  • Bing-Bing Song

    Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, 150081, China

    4 shared publications

Latest Publications

  • Open Access

    Trends of older gastric cancer incidence, mortality, and survival in the highest gastric cancer risk area in China: 2010–2019 and prediction to 2024

    by Penghui Niu, Fan Zhang, Deyuan Ma, Xiadong Zhou, Yitong Zhu, Xiaoyi Luan, Lulu Zhao, Wanqing Wang, Xiaojie Zhang, Xue Han, et al.

    Gastric cancer is a major health problem worldwide, with a high incidence among older adults. Given the aging overall population, it was crucial to understand the current burden and prospective trend of older gastric cancer. This study aimed to analyze the temporal trends of the incidence, mortality, and survival of older gastric cancer in the highest gastric cancer risk area in China from 2010 to 2019, and to predict the future burden of older gastric cancer up to 2024. The study was conducted in Gansu province, an area characterized by the highest gastric cancer incidence and mortality in China. The registration data of gastric cancer incidence and mortality from 2010 to 2019 were pooled from registries in the Gansu Cancer Registration System, while survival data were collected from the First Hospital of Lanzhou University, Lanzhou University Second Hospital, and Gansu Cancer Hospital. Chinese standard population in 2000 and the Segi’s world standard population were applied to calculate the age-standardized rate. Joinpoint regression was used to analyze the average annual percentage change (AAPC) in cancer incidence and mortality. Autoregressive Integrated Moving Average (ARIMA) models were employed to generate forecasts for incidence and mortality from 2020 to 2024. Based on registry data from 2010 to 2019, the incidence and mortality rates of gastric cancer among older adults remained stable. The incidence rates declined from 439.65 per 100,000 in 2010 to 330.40 per 100,000 in 2019, with an AAPC of -2.59% (95% confidence interval[CI], -5.14 to 0.04, P = 0.06). Similarly, the mortality rate changed from 366.98 per 100,000 in 2010 to 262.03 per 100,000 in 2019, with an AAPC of -2.55% (95% CI, -8.77–4.08%, P = 0.44). In the hospital-based cohort, the decline in survival rates was reported among older patients with gastric cancer in the highest gastric cancer risk area in China, with the 3-year overall survival (OS) decreasing from 58.5% (95% CI, 53.5–63.2%) in 2010 to 34.4% (95%CI, 32.1–36.7%) in 2019, and the 3-year progression-free survival (PFS) decreasing from 51.3% (95%CI, 47.5–55.1%) in 2010 to 34.2% (95%CI, 32.0–36.3%) in 2019, respectively. Moreover, forecasts generated by ARIMA models revealed a significant decline in the incidence and mortality of older gastric cancer in China from 2020 to 2024. Specifically, the incidence rate of older gastric cancer was expected to decrease from 317.94 per 100,000 population in 2020 to 205.59 per 100,000 population in 2024, while the anticipated mortality rate was estimated to decrease from 222.52 per 100,000 population in 2020 to 186.22 per 100,000 population in 2024. From 2010 to 2019, the incidence and mortality of older gastric cancer remained stable in the highest gastric cancer risk area in China, while the survival rates showed a decline. Based on the ARIMA models, it was anticipated that there might be a continued decline in older gastric cancer incidence and mortality in the highest-risk area in China over the next five years.


    • 20 February 2024
      • Vol. 27  (2) , 88-95
    Open Access

    2010-2019年甘肃省肿瘤登记地区肺癌发病的流行病学特征分析

    by Zhaoxia Lu, Jixiong Ma, Juhong Ma, Hong Zhou, Juanjuan Xue, Gaoheng Ding, Yindi Wang, Zhen Lv, Yuqin Liu, Ben Wang, et al.

    背景与目的 肺癌是中国发病率最高、疾病负担最重的恶性肿瘤。近年来,肺癌呈高发趋势,严重影响人群健康。本文通过分析甘肃省肿瘤登记地区2019年肺癌发病特征及2010-2019年发病率趋势,为甘肃省肺癌防控策略制定提供参考依据。 方法 通过分析甘肃省肿瘤登记地区2019年肺癌发病个案,计算发病率、中标发病率、世标发病率等相关指标;采用Joinpoint计算年度变化百分比(annual percent change, APC),进行趋势分析。 结果 2019年甘肃省共报告肺癌新发病例3757例,占所有新发恶性肿瘤的14.96%,肺癌发病率、中标率、世标率分别为40.52/10万、30.91/10万和25.86/10万,0-74岁累积率、35-64岁截缩率分别为3.23%和40.03/10万。肺癌发病随着年龄增长而上升,在≥40岁组高发,男、女性人群分别在≥75岁组、≥80岁组达到发病高峰。2010-2019年甘肃省肿瘤登记地区肺癌粗发病率总体呈上升趋势,且上升速度较快,APC为5.39%(P 结论 2010-2019年甘肃省肿瘤登记地区肺癌发病率呈现逐年上升趋势,不同性别、地区及年龄组人群肺癌发病存在差异,应针对肺癌发病重点人群开展综合防控工作。

  • Open Access

    Trend in incidence and mortality of cancer, a high -risk area in Gansu province: Analysis of the 2010 to 2018 in Gansu Central Cancer Registry

    by Liu Yuqin, Yuan Haoran, Zhu Yitong, Ding Gaoheng, Guzhanuer Niyazi, Zhu Gongjian

    Background: The incidence and mortality of cancer in Gansu Province remain high, especially the digestive system tumors have long been in the top 5, and there is a rising trend. This paper uses the cancer registration data in Gansu Province from 2010 to 2018 to analyze the trend of trend changes, and provides information for the government basis for decision-making.Methods: The registration data of cancer incidence, death and population data reported by 23 cancer registration sites in Gansu Province in 2021 were collected, and the data of 15 registration sites met the quality control standards. The incidence (mortality) rate, age-standardized incidence(mortality) rate, cumulative rate(0~74 years old) were calculated according to gender, areas(urban and rural) and age groups. The age-standardized rate was calculated and adjusted by Chinese standard population in 2000(ASIRC, ASMRC) and world standard(Segi’s) population(ASIRW, ASMRW), respectively. Joinpoint Regression Program was used to estimate the annual percentage change(APC),and average annual percentage change(AAPC) to analyze the temporal trends of annual all cancer incidence and mortality rates.Results: In 2018, the number of new cancer cases in Gansu was 13 592, with an incidence rate of 252.98/105, ASIRC and ASIRW were 189.79/105 and 205.89/105 respectively; there were 7,568 cancer deaths in the province, with a mortality rate of 140.86/105, ASMRC and ASMRW were 103.40/105 and 116.83/105 respectively. The ASIRC and ASMRC in urban areas were lower than those in rural areas. The incidence of cancer in males and females peaked in the 80-84 and 75-79 age groups, respectively, and the mortality rates of cancer in both males and females peaked in the 80-84 age groups. From 2010 to 2018, the ASIRC of cancer in the cancer registration areas of Gansu Province showed a downward trend (AAPC, -1.7%, 95%CI, -4.4%-10%), and the difference was not statistically significant (P>0.05). ASMRC showed a downward trend (AAPC, -3.9%, 95%CI,-10.0%-2.7%), the difference was not statistically significant (P>0.05).Conclusions: Digestive tract cancer, lung cancer and female breast cancer have high morbidity and mortality in Gansu Province, and are the main cancer types for the prevention and control of cancer in Gansu Province. According to the epidemic characteristics of cancer, multi-dimensional joint efforts should be made to promote the prevention of cancer populations in our province and reduce the disease burden of cancer in Gansu Province.


  • Health-related quality of life and utility scores of patients with breast neoplasms in China: A multicenter cross-sectional survey

    by Le Wang, Ju-Fang Shi, Juan Zhu, Hui-Yao Huang, Ya-Na Bai, Guo-Xiang Liu, Xian-Zhen Liao, A-Yan Mao, Jian-Song Ren, Xiao-Jie Sun, et al.


  • Open Access

    Medical expenses of urban Chinese patients with stomach cancer during 2002–2011: a hospital-based multicenter retrospective study

    by Ju-Fang Shi, Lan-Wei Guo, Hui-Yao Huang, Neng-Liang Yao, Ji-Yong Gong, Ya-Wen Sun, Guo-Xiang Liu, A-Yan Mao, Xian-Zhen Liao, Ya-Na Bai, et al.

    In China, stomach cancer is the third most common cancer and the third leading cause of cancer death. Few studies have examined Chinese stomach cancer patients’ medical expenses and their associated trends. The Cancer Screening Program in Urban China (CanSPUC) is a Major Public Health Project funded by the central government. Through this project, we have extracted patients’ medical expenses from hospital billing data to examine the costs of the first course treatments (which refers to 2 months before and 10 months after the date of cancer diagnosis) in Chinese patients with stomach cancer and the associated trends. The expense data of 14,692 urban Chinese patients with stomach cancer were collected from 40 hospitals in 13 provinces. We estimated the inflation-adjusted medical expenses per patient during 2002–2011. We described the time trends of medical expenses at the country-level, and those trends by subgroup, and analyzed the compositions of medical expenses. We constructed the Generalized Linear Mixed (GLM) regression model with Poisson distribution to examine the factors that were associated with medical expenses per patient. The average medical expenses of the first course treatments were about 43,249 CNY (6851 USD) in 2011, more than twice of that in 2002. The expenses increased by an average annual rate of 7.4%. Longer stay during hospitalization and an increased number of episodes of care are the two main contributors to the expense increase. The upward trend of medical expenses was observed in almost all patient subgroups. Drug expenses accounted for over half of the medical expenses. The average medical expenses of the first course (2 months before and 10 months after the date of cancer diagnosis) treatments per stomach cancer patient in urban China in 2011 were doubled during the previous 10 years, and about twice as high as the per capita disposable income of urban households in the same year. Such high expenses indicate that it makes economic sense to invest in cancer prevention and control in China.


  • Open Access

    Medical expenditure for esophageal cancer in China: a 10-year multicenter retrospective survey (2002–2011)

    by Lan-Wei Guo, Hui-Yao Huang, Ju-Fang Shi, Li-Hong Lv, Ya-Na Bai, A-Yan Mao, Xian-Zhen Liao, Guo-Xiang Liu, Jian-Song Ren, Xiao-Jie Sun, et al.

    Esophageal cancer is associated with substantial disease burden in China, and data on the economic burden are fundamental for setting priorities in cancer interventions. The medical expenditure for the diagnosis and treatment of esophageal cancer in China has not been fully quantified. This study aimed to examine the medical expenditure of Chinese patients with esophageal cancer and the associated trends. From 2012 to 2014, a hospital-based multicenter retrospective survey was conducted in 37 hospitals in 13 provinces/municipalities across China as a part of the Cancer Screening Program of Urban China. For each esophageal cancer patient diagnosed between 2002 and 2011, clinical information and expense data were extracted by using structured questionnaires. All expense data were reported in Chinese Yuan (CNY; 1 CNY = 0.155 USD) based on the 2011 value and inflated using the year-specific health care consumer price index for China. A total of 14,967 esophageal cancer patients were included in the analysis. It was estimated that the overall average expenditure per patient was 38,666 CNY, and an average annual increase of 6.27% was observed from 2002 (25,111 CNY) to 2011 (46,124 CNY). The average expenditures were 34,460 CNY for stage I, 39,302 CNY for stage II, 40,353 CNY for stage III, and 37,432 CNY for stage IV diseases (P < 0.01). The expenditure also differed by the therapy type, which was 38,492 CNY for surgery, 27,933 CNY for radiotherapy, and 27,805 CNY for chemotherapy (P < 0.05). Drugs contributed to 45.02% of the overall expenditure. These conservative estimates suggested that medical expenditures for esophageal cancer in China substantially increased in the last 10 years, treatment for early-stage esophageal cancer costs less than that for advanced cases, and spending on drugs continued to account for a considerable proportion of the overall expenditure.


  • Open Access

    Expenditure and financial burden for the diagnosis and treatment of colorectal cancer in China: a hospital-based, multicenter, cross-sectional survey

    by Hui-Yao Huang, Ju-Fang Shi, Lan-Wei Guo, Ya-Na Bai, Xian-Zhen Liao, Guo-Xiang Liu, A-Yan Mao, Jian-Song Ren, Xiao-Jie Sun, Xin-Yu Zhu, et al.

    The increasing prevalence of colorectal cancer (CRC) in China and the paucity of information about relevant expenditure highlight the necessity of better understanding the financial burden and effect of CRC diagnosis and treatment. We performed a survey to quantify the direct medical and non-medical expenditure as well as the resulting financial burden of CRC patients in China. We conducted a multicenter, cross-sectional survey in 37 tertiary hospitals in 13 provinces across China between 2012 and 2014. Each enrolled patient was interviewed using a structured questionnaire. All expenditure data were inflated to the 2014 Chinese Yuan (CNY; 1 CNY = 0.163 USD). We quantified the overall expenditure and financial burden and by subgroup (hospital type, age at diagnosis, sex, education, occupation, insurance type, household income, clinical stage, pathologic type, and therapeutic regimen). We then performed generalized linear modeling to determine the factors associated with overall expenditure. A total of 2356 patients with a mean age of 57.4 years were included, 57.1% of whom were men; 13.9% of patients had stage I cancer; and the average previous-year household income was 54,525 CNY. The overall average direct expenditure per patient was estimated to be 67,408 CNY, and the expenditures for stage I, II, III, and IV disease were 56,099 CNY, 59,952 CNY, 67,292 CNY, and 82,729 CNY, respectively. Non-medical expenditure accounted for 8.3% of the overall expenditure. The 1-year out-of-pocket expenditure of a newly diagnosed patient was 32,649 CNY, which accounted for 59.9% of their previous-year household income and caused 75.0% of families to suffer an unmanageable financial burden. Univariate analysis showed that financial burden and overall expenditure differed in almost all subgroups (P < 0.05), except for sex. Multivariate analysis showed that patients who were treated in specialized hospitals and those who were diagnosed with adenocarcinoma or diagnosed at a later stage were likely to spend more, whereas those with a lower household income and those who underwent surgery spent less (all P < 0.05). For patients in China, direct expenditure for the diagnosis and treatment of CRC seemed catastrophic, and non-medical expenditure was non-ignorable. The financial burden varied among subgroups, especially among patients with different clinical stages of disease, which suggests that, in China, CRC screening might be cost-effective.


  • The China Cancer Screening Trial Feasibility Study

    by Min Dai, Ping Hu, Ju-Fang Shi, Jian-Song Ren, Xian-Zhen Liao, Ling-Bin Du, Yu-Qin Liu, Zhao-Li Chen, Ning Wu, Qian Liu, et al.


    • 1 June 2007
      • Vol. 29  (3) , 394-7

    [Effects of oxidative stress on the expression of endothelial-leukocyte adhesion molecule-1 in porcine trabecular meshwork cells].

    by Qi Zhou, Yu-Qin Liu, Jia-Liang Zhao, Hua Zhang

    To investigate the effects of oxidative stress on the expression of endothelialleukocyte adhesion molecule-1 (ELAM-1) in porcine trabecular meshwork cells and to elucidate the relationship between the expression of ELAM-1 and IL-1alpha. Primary cultured porcine trabecular meshwork cells were cultured without serum and treated with 1 mmol/L H2O2 with or without pretreatment of IL-1ralpha of different concentrations. The expression of ELAM-1 was tested by immunocytochemistry. ELAM-1 immunocytochemistry staining was positive in the H2O2-treated porcine trabecular meshwork cells. It was negative in the porcine trabecular meshwork cells pretreated with IL-1alpha of high concentrations (180 microg/ml and 600 microg/ml). Oxidative stress can induce the expression of ELAM-1 in porcine trabecular meshwork cells. In the in vitro cell system, IL-1ralpha of high concentration can inhibit the expression of ELAM-1 induced by oxidative stress.


    • 1 September 2004
      • Vol. 40  (9) , 614-9

    [The effect of endothelial leukocyte-adhesion molecule-1 on the shape and cytoskeleton of porcine trabecular meshwork cells].

    by Qi Zhou, Jia-Liang Zhao, Yu-Qin Liu

    To study the effects of endothelial leukocyte-adhesion molecule-1 (ELAM-1) on the shape and actin cytoskeleton of cultured porcine trabecular meshwork cells (PTCs). The cultured PTCs were stimulated by interleukin-1 (IL-1) and conjugated by ELAM-1 antibody or further cross-linked by IgG. Immunocytochemical procedures were used to study the expression of ELAM-1 and FITC-phalloidin was used to stain the actin filaments on PTCs; phase contrast microscope was employed to observe the dynamic changes of cellular shape and the intercellular conjunction and confocal microscope was used to observe the changes of actin and cellular thickness. IL-1 treatment increased the expression of ELAM-1 in PTCs which resulted in enlarged intercellular space in PTCs with more rounded and stereoscopic morphology after specific antibody conjugation or IgG cross linking. In addition, actin filaments became sparse, cellular rigidity decreased, and the cellular thickness increased after these treatments. Our results demonstrated that IL-1 activated PTCs can express ELAM-1 and interaction of ELAM-1 with specific antibodies and cross linking with IgG, induced a rounding-up of PTCs. This change in cell shape may be due to its action on the actin cytoskeleton.